Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...

Nigeria has scored zero on obesity treatment and physical activity in a new global assessment of how countries are responding ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

As obesity medicine continues to evolve, integrating sleep health into obesity treatment plans is essential.Poor sleep ...

Rhythm Pharmaceuticals said its Phase 3 trial for setmelanotide for patients with rare, genetically-driven obesities did not meet its primary endpoints.

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent ...

Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of ...